Fundus changes of patients with intraocular lymphoma after chemotherapy
LI Ying1, ZHANG Hongtao2
1. Senior Department of Ophthalmology, the First Medical Center, Chinese PLA General Hospital, Beijing 100853, China; 2. Eye Institute,Senior Department of Ophthalmology, the Third Medical Center of Chinese PLA General Hospital, Beijing 100039, China
Abstract：Objective To observe the fundus characteristics and changes of patients with intraocular lymphoma after chemotherapy. Methods A retrospective analysis of 11 patients (15 eyes) with intraocular lymphoma who were treated in the Department of Ophthalmology of the First Center of Chinese PLA General Hospital from January 2015 to December 2021 involved 7 males and 4 females, ranging in age from 47 to 67, with an average age of 55.9. Results Eleven patients (11 eyes) were diagnosed with lymphoma at other sites combined with intraocular lymphoma. After local chemotherapy or combined systemic treatment, ocular lymphoma has a good atrophy effect, and no central nervous system involvement has been observed so far. Chemotherapy-related retinopathy occurred in 7 patients (7 eyes) and optic neuropathy in 7 patients (9 eyes) within 2 years. No progressive changes were observed in fundus for 1 year after symptomatic treatment, and the condition was stable. Three patients (6 eyes) were diagnosed with lymphoma at other sites and received chemotherapy. Chemotherapy-associated optic neuropathy and chemotherapy-associated retinopathy were diagnosed within 1 year. The patients were followed up for 1 year after symptomatic treatment. Fundus lesions did not progress and the condition was stable. One patient (1 eye) developed idiopathic retinal hemorrhage in one eye within 1 year after diagnosis of lymphoma elsewhere and received chemotherapy. Symptomatic ophthalmologic treatment was given. During the 1-year follow-up, the fundus lesions did not progress and the condition was stable. Conclusions The incidence of chemotherapeutic optic neuroretinopathy is very high in patients with systemic lymphoma combined with intraocular lymphoma, whether receiving intraocular chemotherapy or intraocular chemotherapy combined with systemic chemotherapy. Eye and systemic symptomatic treatment can stabilize or slow down the occurrence and progression of the fundus lesions and reduce central nervous involvement.
Davis J L. Intraocular lymphoma: a clinical perspective[J]. Eye(Lond), 2013, 27(2):153-162.
[2]
Kvopka M, Lake S R, Smith J R. Intraocular chemotherapy for vitreoretinal lymphoma: a review[J]. Clin Exp Ophthalmol, 2020, 48(2): 240-248.
[3]
Sagoo M S, Mehta H, Swampillai A J, et al. Primary intraocular lymphoma[J]. Surv Ophthalmol, 2014, 59(5): 503-516.
[4]
Bever G J, Kim D J, Afshar A R, et al. Therapeutic vitrectomy as an adjunct treatment to systemic chemotherapy for intraocular lymphoma[J]. Retin Cases Brief Rep, 2020, 14(2):116-119.
[5]
Smith J R, Pe’er J, Belfort R N, et al. Proceedings of the Association for Research in Vision and Ophthalmology and Champalimaud Foundation Ocular Oncogenesis and Oncology Conference[J]. Transl Vis Sci Technol, 2018, 8(1):9.
Peterson K, Gordon K B, Heinemann M H, et al. The clinical spectrum of ocular lymphoma[J]. Cancer, 1993, 72(3): 843-849.
[10]
Rooij J L, Tokarska K A, Loon N H, et al. Central nervous system progression in primary vitreoretinal lymphoma with bilateral and unilateral involvement: a systematic review and meta-analysis[J]. Cancers(Basel), 2022, 14(12): 2967.
Chan C C, Rubenstein J L, Coupland S E, et al. Primary vitreoretinal lymphoma: a report from an international primary central nervous system lymphoma collaborative group symposium[J]. Oncologist, 2011, 16(11): 1589-1599.
[13]
Hoang X K, Bessell E, Bromberg J, et al.Diagnosis and treatment of primary CNS lymphoma in immune competent patients: guidelines from the european association for neuro-oncology[J].Lancet Oncol, 2015, 16(7) : 322-332.
[14]
Hashida N, Ohguro N, Nishida K. Efficacy and complications of intravitrealrituximab injection for treating primary vitreoretinal lymphoma[J]. Transl Vis Sci Technol, 2012, 1(3) : 15-18.
[15]
Castellino A, Pulido J S, Johnston P B, et al. Role of systemic high-dose methotrexate and combined approaches in the management of vitreoretinal lymphoma: A single center experience 1990-2018[J]. Am J Hematol, 2019, 94(3): 291-298.
2023, Vol. 34 
